Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis

被引:16
作者
Chen, Zhaoyan [1 ]
Tian, Fangyuan [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Pharm, Chengdu, Peoples R China
[2] Sichuan Univ, West China Sch Publ Hlth, Dept epidemiol & Hlth Stat, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp 4, Chengdu, Peoples R China
关键词
COVID-19; Azvudine; Randomized controlled trials; SARS-CoV-2; Meta-analysis; 2'-DEOXY-2'-BETA-FLUORO-4'-AZIDOCYTIDINE;
D O I
10.1016/j.heliyon.2023.e20153
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction: Azivudine has undergone a few randomized controlled trials (RCTs) as of late. This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety. Methods: Through January 20, 2023, systematic searches of PubMed, Embase, ClinicalTrials.gov, International Clinical Trials Registry Platform (ICTRP), Cochrane Central Register of Controlled Trials (CENTRAL), and MedRxiv were conducted to find the RCTs. The included studies' bias risk was evaluated using the Cochrane Handbook for Systematic Reviews of Interventions. Meta analysis was performed using Revman 5.4 (PROSPERO Code: CRD42023395022).Results: A total of five RCTs with 1142 COVID-19 patients, 575 of whom received azvudine, were included. Additionally, seven RCTs are currently being conducted. In terms of clinical improvement and PT-PCR (reverse transcription polymerase chain reaction) negativity, the azvudine group had a greater patient percentage than the usual treatment or placebo group. It also took less time for the PT-PCR to become negative. In comparison to the placebo or standard treatment groups, the frequency of adverse events was reduced in the azvudine group (risk ratio [RR] = 0.89, 95% confidence interval [CI]: 0.80 to 0.99) and major adverse events (RR = 0.63, 95% CI: 0.22 to 1.79) groups.Conclusions: Without the burden of side effects, azvudine can hasten the clinical symptoms of COVID-19 patients and PT-PCR negative. It will take more extensive research to confirm these conclusions.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials
    Kamel, Ahmed M.
    Monem, Mona S. A.
    Sharaf, Nour A.
    Magdy, Nada
    Farid, Samar F.
    REVIEWS IN MEDICAL VIROLOGY, 2022, 32 (01)
  • [22] Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19: A systematic review and meta-analysis
    Ansari, Saad Ali
    Merza, Nooraldin
    Salman, Madiha
    Raja, Adarsh
    Sayeed, Bushra Zafar
    Rahman, Hafsah Alim Ur
    Bhimani, Sunaina
    Shaikh, Afrah Saeed
    Naqi, Unaiza
    Farooqui, Areeba
    Afridi, Simra
    Feroze, Ahsan
    Hameed, Ishaque
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (04)
  • [23] Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis
    Sarma, Phulen
    Bhattacharyya, Anusuya
    Kaur, Hardeep
    Prajapat, Manisha
    Prakash, Ajay
    Kumar, Subodh
    Bansal, Seema
    Kirubakaran, Richard
    Reddy, Dibbanti Harikrishna
    Muktesh, Gaurav
    Kaushal, Karanvir
    Sharma, Saurabh
    Shekhar, Nishant
    Avti, Pramod
    Thota, Prasad
    Medhi, Bikash
    INDIAN JOURNAL OF PHARMACOLOGY, 2020, 52 (06) : 535 - 550
  • [24] Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis
    Rezaei, Soheila
    Fatemi, Behzad
    Karimi Majd, Zahra
    Minaei, Hossein
    Peikanpour, Mohammad
    Anjidani, Nassim
    Taheri, Ali
    Dastan, Farzaneh
    Mosaed, Reza
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (05) : 499 - 511
  • [25] Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
    Alhumaid, Saad
    Al Mutair, Abbas
    Al Alawi, Zainab
    Alhmeed, Naif
    Zaidi, Abdul Rehman Zia
    Tobaiqy, Mansour
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2020, 5 (04)
  • [26] Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs
    Ye, Xiangrong
    Li, Ye
    Luo, Feng
    Xu, Zhibin
    Kasimu, Kaidirina
    Wang, Juan
    Xu, Peihang
    Tan, Chunjiang
    Yi, Hui
    Luo, Yifeng
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [27] Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis
    Toro-Huamanchumo, Carlos J.
    Benites-Meza, Jerry K.
    Mamani-Garcia, Carlos S.
    Bustamante-Paytan, Diego
    Gracia-Ramos, Abraham Edgar
    Diaz-Velez, Cristian
    Barboza, Joshuan J.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [28] Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis
    Di Gennaro, Francesco
    Guido, Giacomo
    Frallonardo, Luisa
    Segala, Francesco Vladimiro
    De Nola, Rosalba
    Damiani, Gianluca Raffaello
    De Vita, Elda
    Totaro, Valentina
    Barbagallo, Mario
    Nicastri, Emanuele
    Vimercati, Antonella
    Cicinelli, Ettore
    Liuzzi, Giuseppina
    Veronese, Nicola
    Saracino, Annalisa
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [29] Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis
    Francesco Di Gennaro
    Giacomo Guido
    Luisa Frallonardo
    Francesco Vladimiro Segala
    Rosalba De Nola
    Gianluca Raffaello Damiani
    Elda De Vita
    Valentina Totaro
    Mario Barbagallo
    Emanuele Nicastri
    Antonella Vimercati
    Ettore Cicinelli
    Giuseppina Liuzzi
    Nicola Veronese
    Annalisa Saracino
    BMC Infectious Diseases, 23
  • [30] Efficacy and safety of glucocorticoids use in patients with COVID-19: a systematic review and network meta-analysis
    He, Qiaolan
    Wang, Chen
    Wang, Yingqin
    Chen, Guannan
    Zhou, Yue
    Wu, Yuanyuan
    Zhong, Ming
    BMC INFECTIOUS DISEASES, 2023, 23 (01)